Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightParticularly those with myocardial infarction showed more marked metabolic and renal abnormalities than those with ischemic heart disease or angina pectoris, so highlighting the possible use of these biomarkers in tracking disease severity and supporting clinical management of cardiovascular diseases.
📌 3 Maddede Bu Makale
Özet
The correlation between biomarkers endocan and interleukin-10 (IL-10) in patients with various cardiovascular diseases—angina pectoris, ischemic heart disease, and myocardial infarction—is examined in this work. There were 200 participants overall, 50 in each of the three disease groups and a control group of fifty healthy people. Along with other factors including renal function, glucose metabolism, and lipid profile, the study gauged serum levels of endocan and IL-10. With myocardial infarction patients showing the highest levels, results revealed that all patient groups had notably greater levels of endocan and IL-10 than healthy controls. With greater blood urea and serum creatinine levels than those with ischemic heart disease and angina pectoris, the study revealed that patients with myocardial infarction demonstrated notably impaired renal function. Along with a poorer lipid profile comprising increased total cholesterol, triglycerides, and low-density lipoprotein (LDL) levels, individuals with myocardial infarction also had higher fasting glucose and hemoglobin A1c levels. By comparison, the healthy control group had the lowest levels of these biomarkers and indicators. The results imply that levels of endocan and IL-10 could be markers of the degree and progression of cardiovascular disease. Particularly those with myocardial infarction showed more marked metabolic and renal abnormalities than those with ischemic heart disease or angina pectoris, so highlighting the possible use of these biomarkers in tracking disease severity and supporting clinical management of cardiovascular diseases.
Abstract
The correlation between biomarkers endocan and interleukin-10 (IL-10) in patients with various cardiovascular diseases—angina pectoris, ischemic heart disease, and myocardial infarction—is examined in this work. There were 200 participants overall, 50 in each of the three disease groups and a control group of fifty healthy people. Along with other factors including renal function, glucose metabolism, and lipid profile, the study gauged serum levels of endocan and IL-10. With myocardial infarction patients showing the highest levels, results revealed that all patient groups had notably greater levels of endocan and IL-10 than healthy controls. With greater blood urea and serum creatinine levels than those with ischemic heart disease and angina pectoris, the study revealed that patients with myocardial infarction demonstrated notably impaired renal function. Along with a poorer lipid profile comprising increased total cholesterol, triglycerides, and low-density lipoprotein (LDL) levels, individuals with myocardial infarction also had higher fasting glucose and hemoglobin A1c levels. By comparison, the healthy control group had the lowest levels of these biomarkers and indicators. The results imply that levels of endocan and IL-10 could be markers of the degree and progression of cardiovascular disease. Particularly those with myocardial infarction showed more marked metabolic and renal abnormalities than those with ischemic heart disease or angina pectoris, so highlighting the possible use of these biomarkers in tracking disease severity and supporting clinical management of cardiovascular diseases.